Akouos, Inc.

NasdaqGS:AKUS Stock Report

Market Cap: US$491.0m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Akouos Management

Management criteria checks 2/4

Key information

Manny Simons

Chief executive officer

US$3.8m

Total compensation

CEO salary percentage13.97%
CEO tenure6.7yrs
CEO ownership3.3%
Management average tenure2yrs
Board average tenure4.3yrs

Recent management updates

Analysis Article • Jan 10

Did Akouos, Inc. (NASDAQ:AKUS) Insiders Buy Up More Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

Recent updates

Analysis Article • Sep 19

Is Akouos (NASDAQ:AKUS) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 13

Akouos stock rises 11% on FDA nod to start gene therapy trial for hearing loss

The U.S. Food and Drug Administration (FDA) cleared Akouos' (NASDAQ:AKUS) investigational new drug application (IND) seeking to start a phase 1/2 trial of gene therapy therapy AK-OTOF to treat pediatric patients with otoferlin gene (OTOF)-mediated hearing loss. The company said it plans to begin a pediatric phase 1/2 study, which includes children as young as two years of age in the dose-escalation phase (Part A), to evaluate AK-OTOF. "This first in human clinical trial for AK-OTOF is groundbreaking and highlights Akouos’s leadership in the field -- we expect this to be the first clinical trial for a genetic inner ear condition, the first in which an AAV gene therapy is administered to the inner ear, and the first for any inner ear condition to begin in a pediatric population," said Akouos Co-Founder, President and CEO Manny Simons. Based on auditory brainstem response data from nonclinical studies, a one-time administration of AK-OTOF has the potential to deliver durable restoration of auditory function, the company said in a  Sept. 13 press release. AKUS +11.14% to $3.89 premarket Sept. 13
Analysis Article • Jun 04

We Think Akouos (NASDAQ:AKUS) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Feb 19

We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 28

Companies Like Akouos (NASDAQ:AKUS) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 26

Here's Why We're Not Too Worried About Akouos' (NASDAQ:AKUS) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 04

We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 10

Did Akouos, Inc. (NASDAQ:AKUS) Insiders Buy Up More Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Analysis Article • Nov 18

Akouos (NASDAQ:AKUS) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

CEO Compensation Analysis

How has Manny Simons's remuneration changed compared to Akouos's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2022n/an/a

-US$93m

Jun 30 2022n/an/a

-US$96m

Mar 31 2022n/an/a

-US$98m

Dec 31 2021US$4mUS$535k

-US$87m

Sep 30 2021n/an/a

-US$74m

Jun 30 2021n/an/a

-US$64m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$7mUS$446k

-US$49m

Sep 30 2020n/an/a

-US$46m

Jun 30 2020n/an/a

-US$41m

Mar 31 2020n/an/a

-US$30m

Dec 31 2019US$772kUS$350k

-US$26m

Compensation vs Market: Manny's total compensation ($USD3.83M) is above average for companies of similar size in the US market ($USD2.68M).

Compensation vs Earnings: Manny's compensation has been consistent with company performance over the past year.

CEO

Manny Simons (39 yo)

6.7yrs
Tenure
US$3,830,990
Compensation

Dr. Emmanuel Simons, Ph D., M.B.A., also known as Manny, Co-founded Akouos in March 2016 and has been its President and Chief Executive Officer and Director since March 2016. Dr. Simons served as Principal...

Leadership Team

NamePositionTenureCompensationOwnership
Emmanuel Simons
Co- Founder6.7yrsUS$3.83m3.26%
$ 16.0m
Michael McKenna
Co-Founderno dataUS$1.39m0.22%
$ 1.1m
Jennifer Wellman
Chief Operating Officer2.1yrsUS$1.78m0.033%
$ 164.0k
Luk Vandenberghe
Founder & Member of Scientific Advisory Boardno datano datano data
William Sewell
Founder & Member of Scientific Advisory Boardno datano datano data
Richard Smith
Founder & Member of Scientific Advisory Boardno datano datano data
Sachiyo Minegishi
CFO, Treasurer2.1yrsUS$4.72mno data
Stacy Price
Chief Technical Officer1yrno datano data
Aaron Tward
Chief Scientific Officerless than a yearno datano data
Karoline Shair
Senior VP2.8yrsno datano data
Kathleen Reape
Chief Development Officer1.5yrsno datano data
Jay Stella
Senior Vice President & Corporate Strategy1.8yrsno datano data
2.0yrs
Average Tenure
44yo
Average Age

Experienced Management: AKUS's management team is not considered experienced ( 2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Emmanuel Simons
Co- Founder6.7yrsUS$3.83m3.26%
$ 16.0m
Michael McKenna
Co-Founder4.4yrsUS$1.39m0.22%
$ 1.1m
Luk Vandenberghe
Founder & Member of Scientific Advisory Board4.3yrsno datano data
William Sewell
Founder & Member of Scientific Advisory Board4.3yrsno datano data
Richard Smith
Founder & Member of Scientific Advisory Board4.3yrsno datano data
Vicki Sato
Independent Director2.8yrsUS$183.50k0%
$ 0
Edward Mathers
Independent Director5.1yrsUS$189.50kno data
Heather Preston
Independent Director2.8yrsUS$187.00k0.016%
$ 78.2k
Kush Parmar
Independent Director5.1yrsUS$180.50kno data
Sona Ramasastry
Independent Director2.4yrsUS$195.50k0%
$ 0
Arthur Tzianabos
Independent Chairman of the Board4.3yrsUS$213.00k0.073%
$ 357.9k
Jean Bennett
Member of Scientific Advisory Board4.3yrsno datano data
4.3yrs
Average Tenure
59yo
Average Age

Experienced Board: AKUS's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/12/01 15:38
End of Day Share Price 2022/11/30 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Akouos, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
null nullBTIG
Joseph PantginisH.C. Wainwright & Co.